Abstract
FK506 binding proteins (FKBPs) are a family of highly conserved proteins in eukaryotes. The prototype of this protein family, FKBP12, is the binding partner for immunosuppressive drugs FK506 and rapamycin. FKBP12 functions as a cis/trans peptidyl prolyl isomerase (PPIase) that catalyzes interconversion between prolyl cis/trans conformations. Members of the FKBP family contain one or several PPIase domains, which do not always exhibit PPIase activity yet are all essential for their function. FKBPs are involved in diverse cellular functions including protein folding, cellular signaling, apoptosis and transcription. They elicit their function through direct binding and altering conformation of their target proteins, hence acting as molecular switches. In this review, we provide a general summary for the structures and diverse functions of FKBPs found in mammalian cells.
Keywords: Calcineurin, FK506, FK506 binding proteins, immunophilin, mTOR, peptidyl prolyl cis/trans isomerase.
Graphical Abstract
Current Molecular Pharmacology
Title:FK506-Binding Proteins and Their Diverse Functions
Volume: 9
Author(s): Mingming Tong and Yu Jiang
Affiliation:
Keywords: Calcineurin, FK506, FK506 binding proteins, immunophilin, mTOR, peptidyl prolyl cis/trans isomerase.
Abstract: FK506 binding proteins (FKBPs) are a family of highly conserved proteins in eukaryotes. The prototype of this protein family, FKBP12, is the binding partner for immunosuppressive drugs FK506 and rapamycin. FKBP12 functions as a cis/trans peptidyl prolyl isomerase (PPIase) that catalyzes interconversion between prolyl cis/trans conformations. Members of the FKBP family contain one or several PPIase domains, which do not always exhibit PPIase activity yet are all essential for their function. FKBPs are involved in diverse cellular functions including protein folding, cellular signaling, apoptosis and transcription. They elicit their function through direct binding and altering conformation of their target proteins, hence acting as molecular switches. In this review, we provide a general summary for the structures and diverse functions of FKBPs found in mammalian cells.
Export Options
About this article
Cite this article as:
Tong Mingming and Jiang Yu, FK506-Binding Proteins and Their Diverse Functions, Current Molecular Pharmacology 2016; 9 (1) . https://dx.doi.org/10.2174/1874467208666150519113541
DOI https://dx.doi.org/10.2174/1874467208666150519113541 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Curcumin - Properties, Applications and Modification of Structure
Mini-Reviews in Organic Chemistry Bombesin-like Peptides: Candidates as Diagnostic and Therapeutic Tools
Current Pharmaceutical Design Bone Morphogenetic Protein-Smad Pathway as Drug Targets for Osteoporosis and Cancer Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Unequivocal Role of Pyrazine Ring in Medicinally Important Compounds: A Review
Mini-Reviews in Medicinal Chemistry Melatonin: Pharmacology, Functions and Therapeutic Benefits
Current Neuropharmacology ADAM10 as a Therapeutic Target for Cancer and Inflammation
Current Pharmaceutical Design Melatonin and Renal Protection: Novel Perspectives from Animal Experiments and Human Studies (Review)
Current Pharmaceutical Design Targeting Microglial Polarization to Improve TBI Outcomes
CNS & Neurological Disorders - Drug Targets Modulation of Neutrophil Development and Homeostasis
Current Molecular Medicine Modifiers of Risk in BRCA1/2 Mutation Carriers
Current Women`s Health Reviews Small Molecule Complementarity As A Source of Novel Pharmaceutical Agents and Combination Therapies
Current Pharmaceutical Design The Activating Receptors of Natural Killer Cells and Their Inter-Switching Potentials
Current Drug Targets Estrone (E1) Based Esters as Potential Inhibitors of Type 3 17β- hydroxysteroid Dehydrogenase (17β-HSD3) in the Treatment of Hormone-Dependent Prostate Cancer
Letters in Drug Design & Discovery Fluoride Interactions: From Molecules to Disease
Current Signal Transduction Therapy Genetic and Epigenetic Studies for Determining Molecular Targets of Natural Product Anticancer Agents
Current Cancer Drug Targets Endoradiotherapy with Peptides - Status and Future Development
Current Medicinal Chemistry DNA Repair in Premature Aging Disorders and Neurodegeneration
Current Aging Science ADAM28 as a Target for Human Cancers
Current Pharmaceutical Design HIV-Antigens Charged on Phosphorus Dendrimers as Tools for Tolerogenic Dendritic Cells-Based Immunotherapy
Current Medicinal Chemistry Regulation of Angiogenesis by Th1- and Th2-Type Cytokines
Current Pharmaceutical Design